The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces rising concerns about monopolies. A few dominant firms control a significant portion of the market, potentially limiting competition and driving up prices for consumers. This concern raises questions about the long-term impact on patient access to affordab